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PCV13 whereas it was associated with an incremental cost of approximately £9
million vs. NoVac. PPV23 dominated PCV13 from both the third-party payer (TPP)
and the societal perspectives. When compared to NoVac, the incremental CE ratio
(ICER) was estimated at £14,813 and £13,497/QALY gained, from the TPP and the
societal perspective, respectively. CONCLUSIONS: The model suggests that vacci-
nating with PPV23 is cost-effective when compared to both PCV13 and NoVac. As
PPV23 covers 80%-90% of all serotypes causing IPD, it is still cost-effective despite
the recent reduction in IPD incidence in adults. The assumptions around the effi-
cacy of PCV13 are a substantial source of uncertainty.
PIN65
COST-EFFECTIVENESS OF FIRST-LINE ANTIRETROVIRAL REGIMENS FOR
HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN COLOMBIA: AN ANALYSIS OF
LOPINAVIR/RITONAVIR (LPV/R) AND DARUNAVIR PLUS RITONAVIR (DRVRTV)
IN TREATMENT-NAÏVE PATIENTS
Moller J1, Desai K2, Simpson KN3, Baran R4, Dietz B5, Van de Steen O6
1United BioSource Corporation, Eslov, Sweden, 2United BioSource Corporation, London, UK,
3Medical University of South Carolina, Charleston, SC, USA, 4Abbott Laboratories, Abbott Park,
IL, USA, 5Abbott GmbH & Co. KG, Ludwigshafen, Germany, 6Abbott Laboratories, Wavre, IL,
Belgium
OBJECTIVES: Current antiretroviral (ARV) therapy has transformed HIV from an
acute to a chronic disease. Consequently, there are more patients living with HIV
and the cost burden to societies that provide lifetime health care, such as Colom-
bia, is increasing. The value assessment of ARV regimens, therefore, requires a
lifetime horizon to accommodate implications of failure, resistance, switching and
survival. The objective was to perform a cost-effectiveness analysis of two first-line
protease inhibitor-based regimens for HIV-infected, ARV-naïve patients in Colom-
bia: LPV/r versus DRVRTV.METHODS:A previously published discrete event sim-
ulation model of first-line LPV/r and DRVRTV was adapted to comprehensively
represent HIV management in Colombia. The impact of initial treatment on CD4
cell count, viral load, adherence, virologic suppression/failure/rebound, acquired
resistance, and ensuing treatment changes were based on ARTEMIS trial data and
the clinical literature. Up to 3 regimen changes were permitted over the model’s
lifetime horizon. Cardiovascular risk was based on the Framingham risk score.
Clinical measures included AIDS related and non-AIDS related events, AEs, time on
sequential therapies, and cardiovascular events. Outcomes included lifetime costs
and quality adjusted life years (QALYs), discounted at 3% per annum. Perspective
was the Colombian national health care system. Costs for ARVs and medical man-
agement were referenced to Colombia pesos (COP). RESULTS: Initiating LPV/r over
DRVRTV saved COP7,845,894 per patient over a lifetime with similar life expec-
tancy (0.02 years; -0.03 QALYs). Similar rates of death, AIDS events, cancer, and
lipoatrophy/lipodystrophy were predicted for both groups. Lifetime cost of cardio-
vascular events were COP70,020 per patient less in the LPV/r arm. LPV/r was cost
saving at 5 years (COP11,311,677) and was cost-effective across multiple sensitivity
analyses. CONCLUSIONS: Initiating HIV infected, ARV-naïve patients on a LPV/r-
based regimen compared to a DRVRTV-based regimen is cost saving and provides
similar life expectancy. Sensitivity analyses provided confidence around these
point estimates.
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OBJECTIVES: To evaluate the cost effectiveness of vaccinating the Brazilian state of
São Paulo’s population 60 years of age and older with the 13-valent pneumococcal
conjugate vaccine (PCV13) in comparison to the 23-valent pneumococcal polysac-
charide vaccine (PPV23), each as a single dose, from the public payer perspective.
METHODS: In order to estimate the pneumococcal disease costs and impact over a
40-year time horizon period, including acute meningitis (AM), invasive pneumo-
coccal disease (IPD), hospitalized pneumonia (HP) and non-complicated pneumo-
nia (NCP), a patient-level microsimulation model simulating vaccination and out-
comes of one cohort of 4.768.202 individuals 60 years of age and older was adapted.
The probabilities and direct medical costs were extracted from literature review
and national databases, with costs presented in US$2011. The effectiveness mea-
sures were expressed as cases of pneumococcal diseases avoided, overall deaths
avoided, and life years (LYs) saved. Effectiveness of PCV13 was derived from studies
in children and adjusted for age and immune status in the elderly; PPV23 was
assumed not to impact pneumonia based on published meta-analyses. Probabilis-
tic sensitivity analyses were conducted considering key variables. Discount rate of
5% was applied. RESULTS: Vaccinating with PCV13 prevents 281 AM, 3.615 IPD,
56.284 HP, 31.553 NCP and 15.742 deaths, saving 90.596 LYs compared to PPV23.
Total costs including vaccination and medical costs resulted in US$14.449.125 less
for PCV13 compared to PCV23 (US$786.747.906 vs. US$772.298.781). The model
showed robustness through sensitivity analyses.CONCLUSIONS:The analysis sug-
gests that vaccinating adults with PCV13 in Brazil is cost-saving compared to
PPV23. The results in economic and disease burden are substantial and they sup-
port the decision making in favor of PCV13 for its high impact in public health.
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OBJECTIVES: The Brazilian National Immunization Program currently offers 10-
valent Pneumococcal Conjugated Vaccine (PCV10) to all children less than 5 years
of age for free. The current study was developed to compare the costs of PCV13
vaccination plus campaign for corporations, versus a hypothetical scenario where
the corporation would incur in the expenditures to do the campaign as proposed
for PCV13 while vaccinating with free PCV10 under the corporative payer
perspective. METHODS: A cost minimization analysis was developed considering
vaccination costs, campaign and health management costs, wage and productivity
loss from employee absence due to child disease and the vaccinations. Clinical
events were retrieved from Pepe et al 2009, absence days due to health events were
retrieved from the average hospitalization days from DATASUS 2012 and ambula-
tory use was limited to 1 absence day. Total employee absence days were halved
assuming a partner outside the company to take care of the sick child and to take
it to the vaccinations. Average wage was retrieved from the Brazilian Institute for
Geography and Statistics 2011 data (IBGE) and production was estimated from the
indicator ‘revenue generated by the employee’, from a market research developed
by Exame magazine in 2011 using IBGE and the Brazilian Central Bank data. The
base case considered a real scenario from a large corporation in Brazil. Values were
expressed in 2011USD. RESULTS: Independent campaign with zero cost PCV10 and
PCV13 vaccination plus campaign totaled 67,90USD and 114,65USD per employee
respectively. Productivity loss was estimated to be 879,07USD and 667,89USD per
employee for PCV10 and PCV13 respectively. Considering all evaluated costs,
PCV10 and PCV13 totaled 946,97USD and 782,54USD per employee respectively.
CONCLUSIONS: The PCV13 vaccination plus campaign initiative is estimated to
save costs (164,42USD/employee), when compared to developing an independent
campaign, mainly driven by productivity loss at the corporative payer perspective.
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OBJECTIVES: To provide an estimate of the treatment related costs of caspofungin
versus liposomal amphotericin B (L-AmB) in febrile, neutropenic patients with a
presumed fungal infection in the Netherlands. METHODS: : A cost-minimization
analysis (CMA) was conducted based on the results of a head-to-head randomized
clinical trial, in which caspofungin (70mg on day 1, 50mg daily thereafter) was
compared to liposomal amphotericin B (3-5mg/kg daily). The trial showed no sig-
nificant difference in success rates (adults: 33.9% for caspofungin and 33.7% for
L-AmB); therefore, the two drugs can be considered equally efficacious. Main as-
sumptions in the CMA were that no drug was spilled and that the difference in drug
administration costs was negligible and could therefore be ignored. The robustness
of the predicted cost-estimates was tested within several scenario analyses, in-
cluding an analysis in a paediatric population. RESULTS: In the base case analysis,
treatment with caspofungin resulted in cost savings of €6,564 per infected adult
patient; mainly due to lower drug acquisition costs. These savings increased to
€8,024 in a scenario analysis assuming that partly emptied vials will not be stored
and used for another administration (ie. spillage of drugs). An additional scenario
revealed that only at extreme average treatment durations of one drug, a cost
neutral result would be obtained. Comparing both drugs in a paediatric population,
incremental costs of caspofungin over L-AmB ranged from -€2,319 to€1,291 for an
average Dutch child aged 16 (weight 62kg; body surface area 1.725m2) and 2 (weight
12.5kg; body surface area 0.555m2) years old respectively. CONCLUSIONS: The
present analysis shows that treatment with caspofungin results in considerable
cost savings compared to L-AmB for the treatment of febrile, neutropenic adult
patients with a presumed fungal infection in the Netherlands. In pediatric patients
cost consequences are depending on body surface area.
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OBJECTIVES: Streptococcus pneumonia causes invasive pneumococcal diseases (IPD),
meningitis and bacteremia, and non-invasive diseases such as pneumonia and
acute otitis media (AOM), leading to high morbidity and mortality in infants and
elderly in Malaysia. To examine the health and economic impacts of routinely
vaccinating infants with 13-valent pneumococcal vaccine (PCV13) compared to
10-valent pneumococcal conjugate vaccine (PCV10) or no vaccine in Malaysia.
METHODS: A Markov model was adapted with local data to evaluate the potential
public health and economic impact of routine vaccination of infants with PCV10 or
PCV13 over a 10-year time horizon, assuming a 3-dose regimen at 2, 4, 12 months of
age and coverage of 90%. Direct effectiveness of PCV13 and PCV10 was estimated
from clinical trial data while indirect (herd) effectiveness was estimated from U.S.
surveillance data. Epidemiology, serotype coverage, and costs were from published
studies and government websites. One-way and multivariate probabilistic sensi-
tivity analyses were performed to test the robustness of model assumptions.
RESULTS: Compared to no vaccination, universal infant PCV13 vaccination would
avoid 19,833 cases of IPD, 832,687 and 1,705,984 cases of hospitalized and non-
hospitalized pneumonia respectively, and 135,675 cases of AOM with the preven-
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tion of 4,531 deaths from IPD and 34,648 deaths from hospitalized pneumonia over
10 years. Compared to no vaccination, PCV13 vaccination would be cost-effective at
RM21,998 per QALY gained from the societal perspective. Compared to PCV10,
PCV13 vaccination would avoid an additional 9,651 cases of IPD, 392,684 and
980,434 cases of hospitalized and non-hospitalized pneumonia respectively, and
81,118 cases of AOM with the prevention of 18,736 deaths. Compared to PCV10,
PCV13 vaccination would be cost-effective at RM6,315 per QALY gained.
CONCLUSIONS: Universal pediatric PCV13 vaccination in Malaysia was estimated
to reduce the burden of pneumococcal diseases and is expected to be cost-effective
compared with both no vaccination and PCV10.
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OBJECTIVES: Pharmacological approaches available in chronic hepatitis B (CHB)
are based on 48-weeks finite course of peg-interferon (PEG) or continuous admin-
istration of nucleoside analogues. Recent studies gave way to early identification of
responders to PEG with a stopping rule based on virologic and serologic markers at
week 12. Objective of this study is the cost-effectiveness analysis of HBeAg-nega-
tive CHB treatment with PEG with stopping rule and switch to current most effec-
tive analogues, entecavir (ETV) or tenofovir (TDF) in Italy. METHODS: A Markov
model was developed in the states: CHB, virologic response, relapse, HBsAg clear-
ance, compensated and decompensated cirrhosis, hepatocarcinoma, liver trans-
plant, post-liver transplant and death. A systematic review of the clinical and
economic literature was performed to find appropriate information. The simulated
strategies were: 1) No treatment; 2) PEG first-line followed by switch to ETV/TDF for
patients either meeting w-12 stopping rule or not responding/relapsing after the
complete course; 3) First-line ETV/TDF in CHB before progression to compensated
cirrhosis (CC); 4) ETV/TDF treatment delayed until CC. ETV and TDF were consid-
ered alternatively for a total of 8 strategies. Outcomes were quality-adjusted life
years (QALY) and costs, calculated from the Italian NHS perspective. RESULTS: The
strategies provided 10.4, 15.3, 15.0, 12.0 QALYs, for no-treatment, PEGETV/TDF,
ETV/TDF-in-CHB and ETV/TDF-in-CC. No meaningful difference in outcomes was
found when ETV or TDF were considered. The average per-patient lifetime cost was
€27,090, €59,270, €69,050, €33,520 with no-treatment, PEGTDF, TDF-in-CHB and
TDF-in-CC. Costs using ETV were 19%-48% higher. PEGTDF was dominant with
respect to TDF-in-CHB and with an ICER of €6,590/QALY and € 7,750/QALY when
compared to no-treatment and TDF-in-CC.CONCLUSIONS:Non treatment or treat-
ment delayed until cirrhosis yielded the poorest outcomes. The strategy of a PEG
first-line with the stopping rule showed a convenient cost-effectiveness profile,
providing the optimal trade-off between clinical efficacy and costs.
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OBJECTIVES: To evaluate cost–effectiveness of pneumococcal vaccination with
10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate
vaccine (PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine
(PCV-13) and no vaccination in Kazakhstan. METHODS: A steady state model with
a one-year time horizon was developed to project the impact of vaccination on the
incidence of pneumococcal and non-typeable Haemophilus influenzae infections in
children aged 0-10 years. Disease incidence rates for meningitis, bacteremia, pneu-
monia and acute otitis media (AOM) were based on data from the Ministry of
Health, benchmarked with other countries and validated by a group of local ex-
perts. Pneumococcal serotypes distribution is based on 4,752 samples reported by
GAVI for Asian region. Serotypes coverage rates of 65.67% and 69.5% for PHiD-CV
and PCV-13, payer perspective, 31 schedule, no herd protection were assumed.
RESULTS: PHiD-CV and PCV-13 are projected to prevent more cases of invasive
disease (278; 294 respectively), and pneumonia hospitalizations (12270; 12270 re-
spectively) compared to no vaccination. PHiD-CV and PCV-13 are projected to pre-
vent additional myringotomies (1920; 949 respectively) and GP visits due to AOM
(70,057; 34,639 respectively) compared to no vaccination strategy. No difference in
absolute number of death was projected when PHiD-CV is compared with PCV-13.
Vaccinating a birth cohort with PHiD-CV or PCV-13 is expected to generate 4,541
and 4,388, respectively, more QALYs compared to no vaccination. At vaccine steady
state PHiD-CV is projected to generate KZT 1.2M in direct medical cost-savings
compared with PCV-13. Sensitivity analyses indicate that incidence rate of menin-
gitis and bacteremia are the most sensitive parameters in the model.
CONCLUSIONS: Pneumococcal conjugate vaccines would be cost effective inter-
ventions for Kazakhstan. However, PHiD-CV dominates PCV-13 because it has a
larger potential QALY gain and higher cost offset related to the additional benefits
due to AOM reduction.
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OBJECTIVES: To evaluate the cost-effectiveness of palivizumab as respiratory syn-
cytial virus prophylaxis in preterm infants born at 35 weeks’ gestation or earlier,
and to determine how the cost-effectiveness of prophylaxis differs among sub-
groups according to risk factors for RSV-related hospitalization. METHODS: A de-
cision analytic model was designed to assess the cost-effectiveness of prophylaxis
with palivizumab for preterm infants born at  35 weeks’ gestational age and  6
months of age compared with no prophylaxis. And by using this model, subgroup
analyses were conducted to evaluate cost-effectiveness for children with different
risk factors related to RSV hospitalization (gestational age, age at the start of the
RSV season, with chronic lung disease, having siblings at school, discharge through
RSV season). RESULTS: The expected costs and QALYs for preterm infants with
palivizumab prophylaxis were higher than those with no prophylaxis. The incre-
mental cost-effectiveness ratio (ICER) for the preterm infants was 19,928,984 KRW
per QALY. The cost-effectiveness of palivizumab varied among the subgroups with
different risk factors. The prophylaxis with palivizumab may be cost-effective
(based on a threshold of 20,000,000 KRW per QALY) for preterm infants with one or
more risk factors according to the age at the start of the RSV season. The prophy-
laxis with palivizumab for preterm infants was cost-effective for infants under 3
months old with 1 risk factor, infants under 9 months old with 2 risk factors, and
infants under 15 months old with 3 risk factors. CONCLUSIONS: This study found
that prophylaxis with palivizumab is a cost-effective strategy for preterm children
compared with no prophylaxis and has different cost-effectiveness according to
the risk factors because of the influence on the risk of RSV hospitalization. There-
fore, it is reasonable to recommend the use of palivizumab for preterm infants in
subgroup with cost-effectiveness considering the risk factors.
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OBJECTIVES: To calculate the direct medical costs associated with HCV health
states by eliciting expert opinion. METHODS: Portuguese-specific annual direct
medical costs of HCV health states were estimated based on a national expert panel
with 8 clinicians experienced in HCV treatment at the national level. We adopted a
two-stage modified Delphi technique: First, experts independently answered ques-
tions concerning the resource use associated with each HCV-related health state.
Secondly, a consensus meeting was held where experts were encouraged to revise
their earlier answers after the panel discussion. The annual cost for each health
state of HCV disease was thereafter obtained by multiplying unit costs with the
consensus scores for each resource use. Unitary costs were obtained through na-
tional official sources. Fibrosis (F0-F3), compensated cirrhosis (CC), decompensated
cirrhosis (DC), hepatocellular carcinoma (HCC) and liver transplantation were set
as the different HCV health states with relevance for clinical and economic
research. RESULTS: Estimated annual costs per HCV health state were the follow-
ing: fibrosis (F0-F3) was €580, in advanced liver disease, CC was €1,156, whereas DC
was €8,222 for the first year and €9,085 for subsequent years. For HCC first year, the
annual cost was €20,749, whilst €19,088 for subsequent years. For liver transplant,
first year cost was €112,072, while for subsequent years it was €7,558. The consid-
erable difference between the costs associated with the first and subsequent years
is due to the transplant procedure being the cost driver for this health state.
CONCLUSIONS:Overall Cost of illness associated with HCV infection is substantial
in Portugal and increases throughout the liver disease health states. Strategies
aiming to treat HCV infection have the potential to decrease the disease progres-
sion and subsequent total costs associated with HCV-related liver disease. The
results from our research highlight this point and may support cost-effectiveness
analysis in the evaluation of those strategies.
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OBJECTIVES: The excessive and often unnecessary prescription of antibiotics and
the resulting increase in antibiotic resistance poses a serious medical problem. The
analysis provides data for assessing a health insurance company’s strategies aim-
ing to optimize antibiotic prescribing due to a quick C-reactive protein testing.
METHODS: Within a period of 22 months (January 2009 – October 2010), in a pop-
ulation sample of 365 690 insured persons from Slovakia, a connection was studied
between availability of a quick C-reactive protein testing as a service furnished by
medical care providers and a final cost of antibiotic treatment. A health insurance
fund provided data for this analysis. RESULTS: Higher consumption of antibiotics
can be linked to higher resistance to antibiotics. On the other hand this linkage is
not linear. In the analysis, the average expenditure per 1 patient at the level of 1.12
€ can be seen within GPs, where a quick C-reactive protein testing is available. On
the other hand, the average expenditure per 1 patient at the level of 1.35 € can be
seen within GPs, where a quick C-reactive protein testing is not available. The
average expenditure per 1 pediatric patient at the level of 1.64 € can be seen within
pediatric medicine, where a quick C-reactive protein testing is available. However,
the average expenditure per 1 pediatric patient at the level of 2.33 € can be seen
within pediatric medicine, where a quick C-reactive protein testing is not available.
Based on the analysis, we can finalised that in the case of an appropriate use of
C-reactive protein testing with the monitored sample of 365 690 insured persons
within the above mentioned period of 22 months, financial resources in a total
A398 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
